The international guidelines have updated their BC treatment guidelines to include treatment with the PARP inhibitor olaparib for one year after completing chemotherapy, surgery, and radiation (if used) to improve outcomes in patients with an inherited mutation in BRCA1/2 with early-stage, HER2-negative BC who have a high risk for recurrence (113). The gene discussed is BRCA1; the disease is breast cancer.